British Journal of Clinical Pharmacology

Article	Citations
Issue Highlights	84
	82
	71
Issue Information	71
Pharmacokinetics, safety and efficacy study in pregnancy and existing cumulative data/evidence to support clinical use and labelling of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in pre	60
Superiority of ceftazidime off‐label high‐dose regimen in PK/PD target attainment during treatment of extensively drug‐resistant Pseudomonas aeruginosa infections in cancer patients	58
Acalabrutinib CYP3A‐mediated drug–drug interactions: Clinical evaluations and physiologically based pharmacokinetic modelling to inform dose adjustment strategy	58
Anticholinergic deprescribing: A case report demonstrating improved cognition and function with minimal adverse withdrawal effects	52
Pharmacokinetics of the inactive favipiravir metabolite, favipiravir hydroxide (M1), as a proxy for establishing metabolic activity in patients receiving intravenous favipiravir for treatment of SARS‐	51
Design of a pharmacokinetic/pharmacodynamic model for administration of low dose peripheral norepinephrine during general anaesthesia	51
Opioid‐related deaths and their counterpart by occurrence era, age group and coimplicated drugs: Scotland vs. England and Wales	49
Does coprescribing nonsteroidal anti‐inflammatory drugs and oral anticoagulants increase the risk of major bleeding, stroke and systemic embolism?	47
Chemometrics as a valuable tool for evaluating interactions between antiretroviral drugs and food	45
Therapeutic drug monitoring of thiopurines: Effect of reduced 6‐thioguanine nucleotide target levels in inflammatory bowel disease patients	45
Health technology assessment of paediatric medicines: European landscape, challenges and opportunities inside the conect4children project	45
Insights from a pharmacometric analysis of HDMTX in adults with cancer: Clinically relevant covariates for application in precision dosing	45
Lemborexant levels in breast milk after single doses in healthy, lactating women	41
Analysis of factors influencing the relationship between voriconazole plasma concentrations and adverse effects in a paediatric population	40
Letter to the editor concerning the article: ‘The impacts of undetected nonadherence in phase II, III and post‐marketing clinical trials: An overview’	39
Incidence, clinical classification and risk factors of cyclosporin A‐induced liver injury in allogeneic haematopoietic stem cell transplant recipients	37
Model‐based dosing optimization and therapeutic drug monitoring practices of teicoplanin in patients with complicated or non‐complicated methicillin‐resistant staphylococcus aureus infection	37
Case report: Dolutegravir dosing post‐Roux‐en‐Y gastric bypass surgery	36
Drug reaction with eosinophilia and systemic symptoms induced by paclitaxel, a rare combination	35
Comparison of the Liverpool Causality Assessment Tool vs. the Naranjo Scale for predicting the likelihood of an adverse drug reaction: A retrospective cohort study	35
Serum uric acid lowering mediated by glucagon‐like peptide‐1 receptor agonists: Emerging considerations	33

Modelling the progression of illicit substance use patterns from real‐world evidence	33
Effect of oral clonidine on pain reduction in patients with opioid use disorder in the emergency department: A randomized clinical trial	32
Selected Abstracts from Pharmacology 2024	32
Postoperative ileus after digestive surgery: Network meta‐analysis of pharmacological intervention	32
Epidural methadone and morphine pharmacokinetics and clinical effects in healthy volunteers: A randomized, crossover‐design trial	32
Pharmacokinetics, pharmacodynamics and safety assessment of multiple doses of soticlestat in healthy volunteers	32
Cardiovascular events of Bruton's tyrosine kinase inhibitors: A real‐world study based on the United States Food and Drug Administration Adverse Event Reporting System database	31
Triple antithrombotic therapy and dual therapy – What is the evidence base?	30
A scoping review of thresholds for responder and time‐to‐event analysis of patient‐reported outcomes in breast cancer trials	30
Intranasal vitamin B12 administration in elderly patients: A randomized controlled comparison of two dosage regimens	30
Sensitivity of estimated tacrolimus population pharmacokinetic profile to assumed dose timing and absorption in real‐world data and simulated data	29
Prospective evaluation of pregnancy outcomes after gestational exposure to prazosin	28
Quantification of sertraline maternal/fetal ratio and amniotic fluid concentration using a pregnancy physiologically based pharmacokinetic model	27
Letter to the editor of the Brit J Clin Pharmacol on Hartjes et al. 2025 https://doi.org/10.1002/bcp.70176	27
Impact of codeine rescheduling on prescribing of codeine and other opioids: Interrupted time series analyses using Australian general practice data	27
Effects of intraoperative low‐dose esketamine on postoperative pain after vestibular schwannoma resection: A prospective randomized, double‐blind, placebo‐controlled study	26
Understanding the influence of transfusion and blood loss on tranexamic acid concentration in scoliosis surgery with blood loss	26
Population pharmacokinetic modelling of prednisolone in systemic lupus erythematosus patients: Analysis of exposure and disease activity	25
Genetic biomarkers of methotrexate response and safety in Crohn's disease: Data from the Spanish ENEIDA registry	25
A narrative review of vaccine pharmacovigilance during mass vaccination campaigns: Focus on myocarditis and pericarditis after COVID‐19 mRNA vaccination	25
Neck‐vein thrombosis during spaceflight	25
Can nebulised HepArin Reduce morTality and time to Extubation in patients with COVID‐19 Requiring invasive ventilation Meta‐Trial (CHARTER‐MT): Protocol and statistical analysis plan for an investigat	25
A first‐in‐human study of the anti‐inflammatory profibrinolytic TMS‐007, an SMTP family triprenyl phenol	25
Older adults' adherence to medications and willingness to deprescribe: A substudy of a randomized clinical trial	25
Issue Information	24
Hospital pharmacists' opinions on a risk prediction tool for medication‐related harm in older people	24
Predicting outcomes for spinal muscular atrophy: When the diagnosis no longer means what it used to mean	24
Advanced prescription of injectable anticancer drugs: Safety assessment in a European Comprehensive Cancer Centre using the risk matrix approach	24
Medication compliance aids unpackaged: A national survey	24
The impact of a preprescribing formative assessment on learning in final‐year medical students using hospital inpatient electronic prescribing systems	24
Impact of CYP2D6*2A, CYP2D6*4 and CYP3A5*3 genetic polymorphisms on Bisoprolol peak concentration and clinical response in acute coronary syndrome patients	23
Penicillin allergy de‐labelling in the critical care unit: Simulations to design an intravenous drug provocation test that mirrors the plasma profile of an enteral challenge	23
Metabolic fate of drugs of abuse and new psychoactive substances: A pilot study on a novel workflow using a zebrafish embryo model combined with human microdosing	23
Longitudinal monitoring of cabotegravir and rilpivirine exposure from hair strand concentrations	23
Treatment with methylphenidate and the risk of fractures among children and young people: A systematic review and self‐controlled case series study	22
Digital twins: Unlocking comparative evidence that clinical research urgently needs	22
Management of serotonin syndrome (toxicity)	22
	22
Impact of pre‐emptive rapid testing for glucose‐6‐phosphate dehydrogenase deficiency prior to rasburicase administration at a tertiary care centre: A retrospective study	21
Unravelling sources of variability on rocuronium pharmacokinetics: Implications for prolonged recovery in older patients	21
Prednisolone pharmacokinetics after oral prednisone administration in paediatric patients with kidney transplant	21
Metamizole induces voriconazole metabolism and results in subtherapeutic voriconazole concentrations	21
Issue Highlights	21
Comparison of the efficacy and safety of standard‐ and high‐dose daptomycin: A systematic review and meta‐analysis	21
Risk of infection from glucocorticoid and methotrexate interaction in patients with rheumatoid arthritis using biologics: A retrospective cohort study	21
Cost–benefit analysis of screening programme for diabetic retinopathy in Bulgaria	20
From statistical inference to machine learning: A paradigm shift in contemporary cardiovascular pharmacotherapy	20
Prevalence of potentially inappropriate medications among newly treated patients with type 2 diabetes in UK primary care	20
Sentinel dosing: A proposed algorithm to guide decision making on which cohorts in early phase clinical pharmacology trials should use this approach	20
Transgender people in clinical trials of drugs and biologics: An analysis of ClinicalTrials.gov from 2007 to 2023	20

A pharmacometrics model to define docetaxel target in early breast cancer	20
Spotlight commentary: The value of spontaneous reporting systems to detect (the lack of) clinically relevant drug–drug interactions in clinical practice	19
The effects of saffron (Crocus sativus L.) in conjunction with concurrent training on body composition, glycaemic status, and inflammatory markers in obese men with type 2 diabetes m	19
Dose‐dependent glucosuria of DWP16001, a novel selective sodium–glucose cotransporter‐2 inhibitor, in healthy subjects	19
Increase of high‐risk tramadol use and harmful consequences in France from 2013 to 2018: Evidence from the triangulation of addictovigilance data	19
Incorporating the One Health Philosophy into pharmacovigilance: Ecopharmacovigilance	19
Performance of the ChatGPT large language model for decision support in community pharmacy	19
The trajectory of pharmacometrics to support drug licensing and labelling	19
Population pharmacokinetics of mirvetuximab soravtansine in patients with folate receptor‐α positive ovarian cancer: The antibody–drug conjugate, payload and metabolite	19
Spotlight commentary: Innovations in clinical trials	18
Effect of glucagon‐like peptide‐1 receptor agonists on renal function: A meta‐analysis of randomized controlled trials	18
A phase I study to evaluate the safety, tolerance and pharmacokinetics of anti‐Shiga toxin hyperimmune equine F (ab′)2 fragments in healthy volunteers	18
Assessing the feasibility of infusing slow normal saline through a three‐metre‐longline to maintain patency of a peripheral venous cannula: A pilot study	18
Issue Highlights	18
	18
Scalability of effective adherence interventions for patients using cardiovascular disease medication: A realist synthesis‐inspired systematic review	18
	18
Evaluation of adherence to abiraterone therapy in prostate cancer patients based on a population pharmacokinetic model	18
Paliperidone poisoning and measurable plasma concentrations 2.5 years after last administered dose: A case report	18
Optimization of vigabatrin dosage in children with epileptic spasms: A population pharmacokinetic approach	18
Correction	18
Anticoagulation intensity and outcomes among southeast‐Asians with moderate‐to‐severe mitral valve stenosis	18
Precision therapy with quinidine of KCNT1‐related epileptic disorders: A systematic review	17
The efficacy of hydroxychloroquine in paediatric chronic immune thrombocytopenia: A retrospective cohort study	17
Hyperbaric oxygen should not be used routinely for carbon monoxide poisoning	17
Physiologically based pharmacokinetic model for oxcarbazepine active metabolite to predict pharmacokinetics in paediatric patients with renal impairment and adjust dosages	17
Oral paltusotine, a nonpeptide selective somatostatin receptor 2 agonist: Mass balance, absolute bioavailability and metabolism in healthy participants	17
A review on the role of extrapolation as basis for paediatric marketing authorization applications of medicines in the EU	17
Population modelling of nilotinib exposure vs . longitudinal BCR::ABL1 response in patients with chronic phase chronic myeloid leukaemia using a semimech	17
Adverse events associated with monoclonal antibodies used for treatment of COVID‐19: A systematic review and meta‐analysis	17
Cabotegravir PopPK analysis of adults and adolescents living with HIV/at risk for HIV receiving prep	16
Association of state‐level prescription drug monitoring program implementation with opioid prescribing transitions in primary care in Australia	16
A single once daily ABC/DTG/3TC tablet predicts safe and effective exposures in children 3 to <6 kg	16
Issue Highlights	16
Antidepressant and antipsychotic prescribing in patients with type 2 diabetes in Scotland: A time‐trend analysis from 2004 to 2021	16
Single‐ascending dose and food effect studies to assess safety and pharmacokinetics of ainuovirine, a novel non‐nucleoside reverse transcriptase inhibitor, for treatment of HIV‐1 infection	16
Association of renin–angiotensin–aldosterone system inhibition with Covid‐19 hospitalization and all‐cause mortality in the UK biobank	16
Ethical concern regarding the UK PANORAMIC COVID‐19 trial	16
Sodium–glucose cotransporter 2 inhibitor increases risk of urinary tract infection: Evidence from mendelian randomization and meta‐analysis	15
Epigenetic modifications in drug‐induced liver injury: A systematic review	15
Issue Information	15
Development and validation of a clinical risk score nomogram for predicting clozapine plasma concentrations below 350 ng/mL: A retrospective cohort study	15
Assessing the anticholinergic cognitive burden classification of putative anticholinergic drugs using drug properties	15
Population pharmacokinetics of sublingually administered tacrolimus in infants and young children with liver transplantation	15
Cefuroxime axetil dosing regimens and probability of target attainment in adults and children	15
Concomitant use of statins and sodium‐glucose co‐transporter 2 inhibitors and the risk of myotoxicity reporting: A disproportionality analysis	15
Adverse event profiles of PCSK9 inhibitors alirocumab and evolocumab: Data mining of the FDA adverse event reporting system	15
Population pharmacokinetics of cabotegravir following administration of oral tablet and long‐acting intramuscular injection in adult HIV‐1‐infected and uninfected subjects	15
Population pharmacokinetics analysis of guselkumab in healthy subjects and patients with psoriatic arthritis, plaque psoriasis and palmoplantar pustulosis	15
Ocular disorders associated with PCSK9 inhibitors: A pharmacovigilance disproportionality analysis	15
Assessment and evaluation of prescribing competences: A systematic review and recommendations	15
Do we become better prescribers after graduation: A 1‐year international follow‐up study among junior doctors	14
Solanidine‐derived CYP2D6 phenotyping elucidates phenoconversion in multimedicated geriatric patients	14
Infliximab‐induced symmetrical drug‐related intertriginous and flexural exanthema (SDRIFE) in a patient with ulcerative colitis	14
Issue Information	14
Risk of out‐of‐hospital cardiac arrest in patients with epilepsy and users of antiepileptic drugs	14
Concentration–response relationships of dolutegravir and efavirenz with weight change after starting antiretroviral therapy	14
UK Prescribing Safety Assessment (PSA): The development, implementation and outcomes of a national online prescribing assessment	14
	14
A crossover study evaluating the sex‐dependent and sensitizing effects of sleep deprivation using a nociceptive test battery in healthy subjects	14
Issue Information	14
Variability in the prevalence of inappropriate medication use among older adults: A review highlighting the importance of screening methods and database types	14
Student perspectives on AI‐supported formative assessment in pharmacology	14
Preclinical pharmacokinetics of novel long‐acting tenofovir alafenamide/bictegravir solid injectable in rats	14
Positive correlation between organic anion transporter 1B function indicated by plasma concentration of coproporphyrin‐I and blood concentration of cyclosporin A in real‐world patients	14
Antidepressant prescribing patterns and adverse events following introduction of a National Prescribing Indicator to monitor dosulepin usage in Wales	13
Isoniazid level and flu‐like symptoms during rifapentine‐based tuberculosis preventive therapy: A population pharmacokinetic analysis	13
Pro: Oximes should be used routinely in organophosphate poisoning	13
Evaluating the pharmacotherapy of tirzepatide in patients with type 2 diabetes: The consideration of systemic metabolism	13
Identification and comparison of sex‐specific serious adverse drug reactions in spontaneous reports and systematically collected reports (ADRED)	13
Comparing regulatory guidance on risk minimization/mitigation and the Reporting recommendation Intended for pharmaceutical Risk Minimization Evaluation Studies checklist	13
Trends in opioid prescribing in Scandinavian countries from 2010 to 2023: Insights from multi‐metric evaluation	13
Prescriptions of anti‐reflux drugs in neonatology and neonatal intensive care units: A large multicentre observational study (2014–2022)	13
Appraising the visibility, relevance and impacts of clinical pharmacology	13
Results of the first international quality control programme for oral targeted oncolytics	13
Adherence levels and patterns for multiple cardiac medications prescribed to patients with incident atrial fibrillation events	13
Issue Information	13
The cost‐effectiveness of cystic fibrosis transmembrane conductance regulator modulators: A systematic review of economic evaluations	13
Application of immunocapture and nanoflow LC–MS/MS to overcome the barriers to the quantitation of oxytocin in plasma of women in third stage labour	13
Association between use of lubiprostone and headache: A systematic review and meta‐analysis of randomized controlled trials	13

Paediatric and obstetrical pharmacology – Pushing the frontier forward	13
Maternal exposure to folate antagonists and susceptibility to congenital heart disease in offspring: A systematic review and meta‐analysis	13
A population pharmacokinetic–pharmacodynamic model evaluating efficacy of nalbuphine extended‐release in patients with prurigo nodularis	13
Correction to “Incidence and trend of cardiac events among children and young adults exposed to psychopharmacological treatment (2006–2018): A nationwide register‐based study”	12
Addressing the challenges of novel therapies in rare diseases with mechanistic perspectives: Missed opportunities or the way forward?	12
Adopting human factors in early phase and experimental medicine research: A nested pilot study observing controlled human infection with SARS‐CoV‐2	12
Investigation of the absolute bioavailability, mass balance, metabolism, and excretion of the cholesterol 24‐hydroxylase inhibitor soticlestat in healthy volunteers	12
Population pharmacokinetic/target engagement modelling of tozorakimab in healthy volunteers and patients with chronic obstructive pulmonary disease	12
Inter‐regional pharmacokinetics and exposure–response analyses of belimumab in patients with system lupus erythematosus	12
Population pharmacokinetics and exposure–response analysis of durvalumab in patients with resectable stage II to IIIB (N2) NSCLC in the phase III AEGEAN study	12
COVID‐19 severity gradient differentially dysregulates clinically relevant drug processing genes in nasopharyngeal swab samples	12
Effect of lemborexant on pharmacokinetics of clozapine: A potential drug–drug interaction mediated by time‐dependent inhibition of CYP3A4	12
Sustainable medicines development and use: Challenges and opportunities in the sustainable production of active pharmaceutical ingredients	12
Beta‐thalassemia and the advent of new interventions beyond transfusion and iron chelation	12
Effect of mild or moderate hepatic impairment on the pharmacokinetics of risdiplam	12
Estimation of adherence to urate‐lowering therapy in people living with gout using Australia's Pharmaceutical Benefits Scheme and patient‐reported dosing	12
Pharmacoethics and pregnancy: Overcoming the therapeutic orphan stigma	12
Risk of out‐of‐hospital cardiac arrest in antidepressant drug users	12
Pharmacokinetic‐pharmacodynamic (PK/PD) modelling of cotadutide effect in patients with chronic kidney disease and type 2 diabetes mellitus	12
Drug–drug interactions between gender‐affirming hormone therapy and antiretrovirals for treatment/prevention of HIV	12
Disparities in oral anticoagulation initiation in patients with schizophrenia and atrial fibrillation: A nationwide cohort study	12
Effects of ABCB1 polymorphisms on the transport of ponatinib into the cerebrospinal fluid in Japanese Philadelphia chromosome‐positive acute lymphoblastic leukaemia patients	11
Pharmacokinetics of molnupiravir and favipiravir in plasma separation cards from patients with COVID‐19: Agile CST‐2 and CST‐6	11
	11
Issue Information	11
Mindfulness‐Oriented Recovery Enhancement: Implementing an evidence‐based intervention for chronic pain, opioid use, and opioid addiction in clinical settings	11
Multimethod quantitative benefit‐risk assessment of treatments for moderate‐to‐severe osteoarthritis	11
Effect of isotretinoin on CYP2D6 and CYP3A activity in patients with severe acne	11
Clinical pharmacology in adolescent transgender medicine	11
Local variation in low carbon footprint inhalers in pre‐COVID pandemic primary care prescribing guidelines for adult asthma in England and its potential impact	11
External validation of a therapeutic window for risperidone in children with autism spectrum disorder	11
Favipiravir pharmacokinetics in saliva, tears and nasal secretions of hospitalized COVID‐19 patients following intravenous favipiravir administration	11
Concentrations of psychoactive substances in blood samples from non‐fatal and fatal opioid overdoses	11
Issue Information	11
Developing an international concept‐based curriculum for pharmacology education: The promise of core concepts and concept inventories	11
Association between polymorphisms of the VKORC1 and CYP2C9 genes and warfarin maintenance dose in Peruvian patients	11
Potential drug–drug interactions due to concomitant medicine use among people living with HIV on antiretroviral therapy in Australia	11
Safe and supportive prescribing in transgender and non‐binary patients with cancer	11
Altered bile acid and coproporphyrin‐I disposition in patients with autosomal dominant polycystic kidney disease	11
Low‐dose amitriptyline: A potential therapeutic option for chronic pain in older people	11
Assessment of the influence of body fat indices on antihypertensive drug responses	11
Sub‐ and supratherapeutic efavirenz plasma concentrations with risk for HIV therapy failure are mainly genetically explained in Ugandan children: The prospective GENEFA cohort study	11
Safety, tolerability and pharmacokinetics of DNDI‐6148, a novel agent for leishmaniasis: A randomized, controlled, single ascending dose study in healthy participants	11
Prescribing variation across Europe: Insights into prescribing practices and educational needs	11
Effects of nirmatrelvir/ritonavir on midazolam and dabigatran pharmacokinetics in healthy participants	11
Successful treatment of hepatitis C virus infection in patients on anti‐epileptics or mood stabilizers using pharmacokinetic enhancers	11
Solanidine analysis during therapeutic drug monitoring revealed rare CYP2D6 poor metabolizer genotype: A case report	11
Primary nonadherence to drugs prescribed by general practitioners: A Dutch database study	10
Population total and unbound pharmacokinetics and pharmacodynamics of ciprofol and M4 in subjects with various renal functions	10
Semaglutide use is associated with neuromuscular junction degradation in older adults with type II diabetes mellitus	10
Cannabidiol in autism: Clinical pharmacology priorities for trial design	10
Spotlight commentary: New Frontiers in pneumonia treatment	10
Drug shortages. Part 1. Definitions and harms	10
Influence of gut bile acid composition on the glucose‐lowering effect and safety of metformin	10
Nonchemotherapy drug‐induced cytopenias: A cost‐of‐illness study using the microcosting methodology based on real‐world data	10
Spotlight commentary: De‐labelling the truth: Clearing the fog around antibiotic allergy labels	10
Pharmacogenomics in 2023: Big studies, big results, big implications, big responsibilities: Editorial	10
Issue Highlights	10
Off‐label and unlicensed medicine prescribing in university hospital paediatric wards in Finland: A prospective study	10
Identifying and addressing pill aversion in adults without physiological‐related dysphagia: A narrative review	10
Population pharmacokinetics of rotigotine extended‐release microspheres for intramuscular injection in patients with early‐stage Parkinson's disease	10
Pharmacokinetic modelling to enable early attrition of repurposed antiviral drug combination candidates with a high likelihood of failure in COVID‐19	10
Killing several birds with one stone: A multi‐indication population pharmacokinetic model and Bayesian estimator for enteric‐coated mycophenolate sodium	10
Pharmacokinetics of YK‐1169 in healthy subjects and pharmacokinetic/pharmacodynamic analysis by Monte Carlo simulation	10
Pharmacokinetics of subcutaneous and intravenous bolus doses of morphine in palliative care cancer patients receiving infusion of morphine: A pharmacokinetic substudy of a randomized controlled trial	10
Addition of direct oral anticoagulants to the World Health Organization model list of essential medicines for the treatment of atrial fibrillation: An African perspective	10
Non‐compartmental and population pharmacokinetic analysis of dapsone in healthy NIGERIANS: A pilot study	10
Pharmacodynamics, pharmacokinetics and CYP3A4 interaction potential of the selective P2X3 receptor antagonist filapixant: A randomized multiple ascending‐dose study in healthy young men	10
	10
Issue Information	10
Implementability of opioid deprescribing interventions at transitions of care: A scoping review	10
Equity and quality use of medicines in people who present to the Psychiatric Alcohol and Non‐Prescription Drug Assessment Unit	10
Population pharmacokinetic‐pharmacodynamic modelling of platelet time‐courses following administration of abrocitinib	10
Evaluation of acquired antithrombin deficiency in paediatric patients supported on extracorporeal membrane oxygenation	10
Deprescribing anticholinergics—Why clinical significance matters more than p ‐values	10
The impact of curricular revision on student performance in pharmacology assessments	10
A new population pharmacokinetic model for recombinant factor IX‐Fc fusion concentrate including young children with haemophilia B	10
Issue Information	10
AZD0449, an inhaled JAK1 inhibitor, in healthy participants and patients with mild asthma	10
‘Under pressure’: The role of therapeutic drug monitoring in the treatment of hypertension	10
Issue Highlights	10
Medication adherence and hospitalizations in older patients with coronary heart disease in Vietnam	10
Impact of P‐glycoprotein and/or CYP3A4‐interacting drugs on effectiveness and safety of non‐vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: A meta‐analysis	9
Physiologically based pharmacokinetic and pharmacodynamic modelling of alprazolam: Implications for anxiety and addiction	9
A phase 1 trial of AP30663, a KCa2 channel inhibitor in development for conversion of atrial fibrillation	9
Physiologically based pharmacokinetic modelling to inform combination dosing regimens of ceftaroline and daptomycin in special populations	9
Skeletal muscle relaxant drug–drug–drug interactions and unintentional traumatic injury: Screening to detect three‐way drug interaction signals	9
Economic evaluations of therapeutic drug monitoring interventions in acute hospital‐based settings: A systematic review	9
Pharmacokinetic modelling of intravenous immunoglobulin in children with primary immunodeficiencies and secondary antibody deficiencies	9
Intramuscular cabotegravir and rilpivirine concentrations after switching from efavirenz‐containing regimen	9
Pharmacokinetics, pharmacodynamics and urinary recovery of oral lysergic acid diethylamide administration in healthy participants	9
Population pharmacokinetic analysis of dexmedetomidine in children using real‐world data from electronic health records and remnant specimens	9
Pharmacogenomics in clinical practice: Biomarker information in Brazilian drug labels	9
Comprehensive safety assessment of ribociclib: A real‐world analysis using the FDA Adverse Event Reporting System (FAERS) database	9
Exposure–response relationships of mirvetuximab soravtansine in patients with folate receptor‐α‐positive ovarian cancer: Justification of therapeutic dose regimen	9